Overview
Biognosys provides next-generation proteomics solutions for pharmaceutical R&D and life sciences organizations, specializing in mass spectrometry-based protein analysis, proteogenomics, and biomarker discovery. Their platform enables comprehensive protein expression profiling, post-translational modification analysis, and quantitative proteome characterization to support drug development, target validation, and personalized medicine applications.
Frequently asked questions
- What proteomics technologies and methodologies does Biognosys offer?
- Biognosys provides advanced mass spectrometry-based proteomics services including Data-Independent Acquisition (DIA) quantitative proteomics, phosphoproteomics, post-translational modification (PTM) analysis, and proteogenomics applications that combine proteomic data with genomic and transcriptomic information for comprehensive protein characterization.
- How can Biognosys support drug discovery and development programs?
- Biognosys enables therapeutic discovery through precise protein quantification in cells, tissues, and biofluids; identification of drug targets and biomarkers; analysis of protein variants and modifications; and evaluation of drug effects on protein systems. Their services support target validation, biomarker discovery, and personalized therapy development.
- What sample types and throughput capabilities does Biognosys support?
- Biognosys analyzes diverse sample types including cells, tissues, plasma, and formalin-fixed paraffin-embedded (FFPE) tissues. Their platform supports high-throughput analysis with capabilities to measure thousands of proteins across multiple samples simultaneously, enabling both discovery and screening studies with scalable workflows.